Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.

Autor:	Langbaum JB; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Zissimopoulos J; Sol Price School of Public Policy and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA., Au R; Departments of Anatomy & Neurobiology, Neurology and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA., Bose N; Gates Ventures, Kirkland, Washington, USA., Edgar CJ; Cogstate Ltd, Reading, UK., Ehrenberg E; Clara Health, San Francisco, California, USA., Fillit H; Alzheimer's Drug Discovery Foundation, New York, New York, USA., Hill CV; Alzheimer's Association, Chicago, Illinois, USA., Hughes L; Lynne Hughes Consulting, Berkshire, UK., Irizarry M; Eisai, Woodcliff Lake, New Jersey, USA., Kremen S; The Jona Goldrich Center for Alzheimer's and Memory Disorders, Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA., Lakdawalla D; Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA., Lynn N; BrightFocus Foundation, Clarksburg, Maryland, USA., Malzbender K; Gates Ventures, Kirkland, Washington, USA., Maruyama T; Alzheimer's Disease Data Initiative, Kirkland, Washington, USA., Massett HA; National Institute on Aging, Bethesda, Maryland, USA., Patel D; IQVIA, New York, New York, USA., Peneva D; Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA., Reiman EM; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Romero K; Critical Path Institute, Tucson, Arizona, USA., Routledge C; Small Pharma Ltd, London, UK., Weiner MW; Departments of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, University of California San Francisco, San Francisco, California, USA., Weninger S; FBRI, Cambridge, Massachusetts, USA., Aisen PS; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Feb; Vol. 19 (2), pp. 696-707. Date of Electronic Publication: 2022 Aug 10.
DOI:	10.1002/alz.12737
Abstrakt:	Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient-advocacy organizations, philanthropy, non-profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimer's clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panel's recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD. (© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu